| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
We reported tyrosine kinase inhibitor nilotinib showed antimalarial activity both in vitro and in vivo. However, it is clear that Pasmodium dose not have tyrosine kinase, indicate presence of novel mode of action (MOA). To identify the antimalarial MOA of nilotinib, target protein fishing was used for obtaining binding proteins. Five binding proteins were obtained and a part of them were identified endplasmin homolog, RNA helicase (pfeIF4A) and a membrane protein A. PfeIF4A is an indispensable factor for malaria parasite (from PlasmoDB) and it might be lead to development for new target.
Protein expression of pfeIF4A and creating of nilotinib resistant P.falciparum are ongoing to validate the MOA.
|
